A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM)

Trial Profile

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs BGB 3111 (Primary) ; Ibrutinib
  • Indications B cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 07 Jun 2017 Data from this trial will be presented at the 14th International Conference on Malignant Lymphoma (14-ICML) 2017, according to a BeiGene media release.
    • 25 Jan 2017 Status changed from planning to recruiting, as per a BeiGene media release.
    • 10 Nov 2016 According to a BeiGene, Ltd. media release, this trial is likely to initiate in the late 2016 or early 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top